WHAT IS CLAIMED IS:

1. Use of tenecteplase in the manufacture of a medicament for treatment of acute ischemic stroke in a human, wherein the treatment comprises administering tenecteplase in a total dose of 0.05 to 0.5mg/kg, given as an initial bolus dose of 0.05 to 0.15 mg/kg, followed by infusion of an amount equaling the total dose minus the initial dose over a period of 50-90 minutes.

2. Use of tenecteplase according to claim 1 wherein the total dose is 0.2 to 0.3 mg/kg.

3. Use of tenecteplase according to claim 1 or 2 wherein the total dose is 0.25 mg/kg.

4. Use of tenecteplase according to any one of claims 1-3 wherein the initial dose is 0.08 to 0.12 mg/kg bolus.

5. Use of tenecteplase according to any one of claims 1-4 wherein the initial dose is 0.1 mg/kg bolus.

6. Use of tenecteplase according to any one of claims 1-5 wherein the period of infusion is 55-70 minutes.

7. Use of tenecteplase according to any one of claims 1-6 wherein the period of infusion is 60 minutes

8. Use of tenecteplase according to any one of claims 1-7 wherein the total dose is 0.25 mg/kg, given as an initial bolus of 0.1 mg/kg, followed by infusion of 0.15 mg/kg over 60 minutes.

9. Use of tenecteplase according to any one of claims 1-8 wherein the tenecteplase is administered to the human at a time between 15 minutes and 20 hours from the onset of acute ischemic stroke.

10. Use of tenecteplase according to any one of claims 1-9 wherein the tenecteplase is administered to the human at a time between 30 minutes and 6 hours from the onset of acute ischemic stroke.

11. Use of tenecteplase according to any one of claims 1-10 wherein the tenecteplase is administered to the human at a time between 30 minutes and 3 hours from the onset of acute ischemic stroke.

12. Use of tenecteplase according to any one of claims 1-11 wherein the bolus is intravenous.

13. Use of tenecteplase according to any one of claims 1-12 further comprising administering to the human an effective amount of a second medicament, wherein the first medicament is tenecteplase.

14. Use of tenecteplase according to claim 13 wherein the second medicament is a neuroprotective agent, a thrombolytic agent, a glycoprotein IIb IIIa antagonist, or an anti-CD18 antibody.

15. A kit when used according to any one of claima 1-14, the comprising tenecteplase.

16. The kit of claim 15 further comprising a second medicament, wherein the first medicament is tenecteplase.

17. The kit of claim 16 wherein the second medicament is a neuroprotective agent, a thrombolytic agent, a glycoprotein IIb IIIa antagonist, or an anti-CD18 antibody.

CLAIMS

1. Use of tenecteplase in the manufacture of a medicament for treatment of acute ischemic stroke, wherein the medicament is formulated for administration of tenecteplase in a total dose of 0.05 to 0.5 mg/kg to be given as an initial bolus dose of 0.05 to 0.15 mg/kg followed by infusion of an amount equaling the total dose minus the initial dose over a period of 50-90 minutes.

2. Use of tenecteplase according to claim 1 wherein the medicament is formulated for administration of tenecteplase in a total dose of 0.2 to 0.3 mg/kg.

3. Use of tenecteplase according to claim 1 or 2 wherein the medicament is formulated for administration of tenecteplase in a total dose of 0.25 mg/kg.

4. Use of tenecteplase according to any one of claims 1-3 wherein the medicament is formulated to provide an initial bolus dose of tenecteplase at a concentration between 0.08 to 0.12 mg/kg.

5. Use of tenecteplase according to any one of claims 1-4 wherein the medicament is formulated to provide an initial bolus dose of tenecteplase at a concentration of 0.1 mg/kg.

6. Use of tenecteplase according to any one of claims 1-5 wherein the medicament is formulated to provide a total dose minus the initial dose of tenecteplase for infusion over a period of 55-70 minutes.

7. Use of tenecteplase according to any one of claims 1-6 wherein the medicament is formulated to provide a total dose minus the initial dose of tenecteplase for infusion over a period of 60 minutes.

8. Use of tenecteplase according to any one of claims 1-7 wherein the medicament is formulated to provide tenecteplase in a total dose is 0.25 mg/kg, wherein the tenecteplase is to be given as an initial bolus of 0.1 mg/kg, followed by infusion of 0.15 mg/kg over 60 minutes.

9. Use of tenecteplase according to any one of claims 1-8 wherein the medicament is formulated for administration at a time between 15 minutes and 20 hours from the onset of acute ischemic stroke.

10. Use of tenecteplase according to any one of claims 1-9 wherein the medicament is formulated for administration at a time between 30 minutes and 6 hours from the onset of acute ischemic stroke

11. Use of tenecteplase according to any one of claims 1-10 wherein the tenecteplase is formulated for administration at a time between 30 minutes and 3 hours from the onset of acute ischemic stroke.

12. Use of tenecteplase according to any one of claims 1-11 wherein the medicament is formulated for intravenous administration of the initial bolus dose of tenecteplase.

13. Use of tenecteplase according to any one of claims 1-12, wherein the medicament is formulated for administration in combination with an effective amount of a second medicament.

14. Use of tenecteplase according to claim 13 wherein the second medicament is a neuroprotective agent, a thrombolytic agent, a glycoprotein IIb IIIa antagonist, or an anti-CD18 antibody.

15. A kit when used according to any one of claims 1-14, the kit comprising tenecteplase.

16. The kit of claim 15 further comprising a second medicament.

17. The kit of claim 16 wherein the second medicament is a neuroprotective agent, a thrombolytic agent, a glycoprotein IIb IIIa antagonist, or an anti-CD18 antibody.